Global Migraine Drug Market Size To Grow At 15.6% CAGR From 2022 to 2030


As per our research report, theglobal Migraine Drug Market size is estimated to be growing at a CAGR of 15.6% from 2023 to 2030. 

The COVID-19 pandemic has had a major effect on the world's healthcare sector, especially the market for migraine medications. Drug shortages and delivery delays are a result of the pandemic's disruption of pharmaceutical supply networks and manufacturing. In addition, treating COVID-19 patients and controlling the pandemic have taken precedence over other healthcare objectives as a result of the epidemic. Patients delaying or avoiding seeking medical attention for problems unrelated to COVID has reduced the market for migraine medications. The pandemic has also resulted in a decrease in medical visits and procedures, such as imaging and diagnostic testing, which are crucial for the identification and management of migraines. Contrarily, the epidemic has also prompted a rise in distant medical services, such as telemedicine, which has facilitated the provision of healthcare to migraine patients. The trend toward remote medical care has also boosted patient knowledge and understanding of migraines, their causes, and how to treat them. The pandemic has had a complex effect on the migraine medicine industry, causing both supply chain interruptions and drug demand fluctuations as well as a rise in the use of remote medical services. The duration and intensity of the pandemic, the rate of the economy's recovery, and the creation of potent COVID-19 vaccines and treatments will all play a role in how the pandemic will ultimately affect the market for migraine medications.

In adults without a history of any other medical conditions, there are a number of drug solutions for treating and preventing migraines, but they come with serious side effects as well, including weight fluctuations, nausea, and dizziness. Sumatriptan is the safest therapeutic option for pregnant women, and anticonvulsant medications are not advised. The U.S. Food and Drug Administration's approval of a new class of medications created specifically to treat migraines, however, has had a favorable impact on the market. Ajovy, Emgality, and Aimovig (Erenumab) are the newest medications to receive FDA approval. Eli Lilly and Company gained FDA approval for Emgality (galcanezumab-gnlm), a 120 mg injection for the treatment of adult migraines before they occur, in September 2020.

Additionally, the market for migraine drugs is being driven by improved awareness campaigns, the availability of research funding from both public and commercial organizations, an improvement in the reimbursement environment for related treatments, and growing knowledge of the efficacy of such drugs.


  • Throughout the projection period, the category of preventive drugs is anticipated to expand at a CAGR of 15.6%. In the global market for migraine drugs, painkiller sales continue to lead in terms of revenue. Current research focuses on novel action routes include CGRP-based receptor and ligand inhibition, corticotrophin receptor antagonism, and nitrous oxide inhibition. The approval of CGRP monoclonal antibodies is one of the major developments in the preventative business.
  • With the introduction of Aimovig, Amgen and Novartis are the market's first movers in CGRP and would so stand to gain. The development of the target product would also benefit from the attractive reimbursement scenario and an easy-to-use pen-device administration of the medication. Medical professionals and healthcare providers responded favorably to the treatments after their release in Europe and North America in July 2020 and May 2020, respectively.
  • The hospital distribution segment is anticipated to hold the majority of market shares in 2022, due to a large number of people turning toward them for prescribed medicines and treatment. Also, it is anticipated that the segment will continue to hold dominance during the projection period, 2023-2030.
  • The target market's primary geographical region for producing money is still North America. In 2022, the geography division of North America brought in USD 496.7 million. One of the main factors boosting the market growth for migraine drugs in this region is the presence of major market participants, advantageous reimbursements for migraine medications, growing emphasis on precision medicine, and increased awareness of various migraine treatments.
  • In a market that is anticipated to be crowded and competitive with CGRP mAbs from Eli Lilly and Company and Teva Pharma, the launch of Aimovig at a lower-than-anticipated price would improve patient access and support the sales of therapies in the preventative migraine arena.


By Product: 

  • Pain relievers
  • Triptans
  • Opioid medication
  • Anti-nausea drugs
  • Others

By Route of Administration 

  • Oral
  • Injectable
  • Nasal sprays

By Distribution Channel:


  • Retail Stores
  • Others


By Region: 

  • North America 
  • Europe 
  • Asia-Pacific 
  • Rest of the World

Analyst Support

Every order comes with Analyst Support


We offer customization to cater your needs to fullest

Verified Analysis

We value Integrity, quality and authenticity the most